This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Walker, J. E Articles by Margolin, S. B Search for Related Content PubMed PubMed Citation Articles by Walker, J. E Articles by Margolin, S. B Social Bookmarking                         What's this?

Pirfenidone for chronic progressive multiple sclerosis

Board Certified Psychiatry and Neurology, 12870 Hillcrest, Suite #201, Dallas, Texas 75230, USA

Solomon B Margolin

Marnac, Inc., 9400 N. Central Expressway, Suite #305, Dallas, Texas 75231 USA

Current treatment of secondary progressive multiple sclerosis is unsatisfactory in stabilizing or reversing the disabilities associated with the disease. Pirfenidone is a new non-peptide drug which has been shown in vitro and in vivo to decrease synthesis of Tumor Necrosis Factor-alpha (TNF-a) and block receptors for TNF-a. Since TNF-a seems to be a key cytokine in demyelination, a pilot study of oral pirfenidone was undertaken in an open-label baseline vs treatment protocol over a 2-year period in 20 patients. Fourteen (14/20) patients (70%) remained in the study for 2 years. Three (3/20) patients dropped out early because of gastrointestinal adverse reactions, and another three patients dropped out for personal reasons after 1 year (not because of adverse reactions). The remaining patients did not manifest any other drug-related adverse reactions and complications. Improvement or stabilization occurred in most patients at about 3 months, and it was sustained at 6, 12 and 24 months as evaluated by both primary and secondary outcome measures. Magnetic resonance imaging failed to reveal any new lesions. Thus, pirfenidone appears to offer protection against the usual slow progression of the disease. Most patients experienced a distinct decrease in their neurological disability. These findings indicate that an extensive multi-center double blind and placebo controlled trial is warranted.

Key Words: secondary progressive multiple sclerosis • pirfenidone (oral) • tumor necrosis factor-alpha • disease stabilization • disability reduction • clinical trials

Multiple Sclerosis, Vol. 7, No. 5, 305-312 (2001)
DOI: 10.1177/135245850100700506


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Shi, J. Wu, H. Chen, H. Chen, J. Wu, and F. Zeng Single- and Multiple-Dose Pharmacokinetics of Pirfenidone, an Antifibrotic Agent, in Healthy Chinese Volunteers J. Clin. Pharmacol., October 1, 2007; 47(10): 1268 - 1276. [Abstract] [Full Text] [PDF]

				H. Liu, P. Drew, Y. Cheng, and G. A. Visner Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 852 - 858. [Abstract] [Full Text] [PDF]

				J. E Walker, S. N Giri, and S. B Margolin A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis Multiple Sclerosis, April 1, 2005; 11(2): 149 - 158. [Abstract] [PDF]

				J. D Bowen, K. Maravilla, and S. B Margolin Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis Multiple Sclerosis, June 1, 2003; 9(3): 280 - 283. [Abstract] [PDF]